Health-related quality of life (HRQoL) was evaluated in the KEYNOTE-002 study.
HRQoL was maintained to a greater degree with pembrolizumab versus chemotherapy.
In all arms, HRQoL decreased in patients who experienced disease progression.
These data support pembrolizumab for ipilimumab-refractory advanced melanoma.